Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2-advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.

被引：16
|
作者：
Kalinsky, Kevin [1 ]
Bianchini, Giampaolo [2 ]
Hamilton, Erika P. [3 ]
Graff, Stephanie L. [4 ]
Park, Kyong Hwa [5 ]
Jeselsohn, Rinath [6 ]
Demirci, Umut [7 ]
Martin, Miguel [8 ,9 ]
Layman, Rachel M. [10 ]
Hurvitz, Sara A. [11 ,12 ]
Sammons, Sarah L. [6 ]
Kaufman, Peter A. [13 ]
Munoz, Montserrat [9 ,14 ]
Tseng, Ling-Ming [15 ]
Knoderer, Holly [16 ]
Nguyen, Bastien [16 ]
Zhou, Yanhong [16 ]
Ravenberg, Elizabeth [16 ]
Litchfield, Lacey M. [16 ]
Wander, Seth Andrew [17 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[2] IRCCS Osped San Raffaele, Milan, Italy
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Brown Univ, Lifespan Canc Inst, Legorreta Canc Ctr, Providence, RI USA
[5] Korea Univ, Anam Hosp, Dept Internal Med, Div Med Oncol,Coll Med, Seoul, South Korea
[6] Dana Farber Canc Inst, Boston, MA USA
[7] Uskudar Univ, Fac Med, Mem Ankara Hosp, Med Oncol, Ankara, Turkiye
[8] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
[9] GEICAM Spanish Breast Canc Grp, Madrid, Spain
[10] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[11] Univ Washington, Sch Med, Seattle, WA USA
[12] Fred Hutchinson Canc Ctr, Seattle, WA USA
[13] Univ Vermont, Canc Ctr, Burlington, VT 05405 USA
[14] Hosp Clin Barcelona, Barcelona, Spain
[15] Taipei Vet Gen Hosp, Taipei, Taiwan
[16] Eli Lilly & Co, Indianapolis, IN USA
[17] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 17_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.17_suppl.LBA1001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：LBA1001 / LBA1001
页数：1
相关论文
共 50 条
  • [31] Phase II trial of fulvestrant plus enzalutamide in ER+/Her2-advanced breast cancer
    Elias, Anthony D.
    Spoelsta, Nicole
    Vidal, Gregory A.
    Sams, Sharon
    Kabos, Peter
    Diamond, Jennifer R.
    Shagisultanova, Elena
    Afghahi, Anosheh
    Mayordomo, Jose
    McSpadden, Tessa
    Crawford, Gloria
    Carter, Lisa
    Zolman, Kathryn
    Armstead, Stephanie
    Winchester, Alyse
    Borges, Virginia
    Wulfkuhle, Julia
    Petricoin, Emanuel
    Gao, Dexiang
    Richer, Jennifer
    CANCER RESEARCH, 2021, 81 (04)
  • [32] Bireociclib plus fulvestrant for advanced HR+/HER2- breast cancer progressing after endocrine therapy: Interim analysis of a phase 3 trial (BRIGHT-2)
    Wang, Jiayu
    Zhang, Qingyuan
    Li, Huiping
    Tong, Zhongsheng
    Ouyang, Quchang
    Li, Huihui
    Teng, Yuee
    Wang, Biyun
    Sun, Tao
    Wang, Jingfen
    Li, Wei
    Niu, Zhaofeng
    Li, Hongsheng
    Gong, Chang
    Wang, Li
    Liu, Fei
    Wang, Shuya
    Meng, Yaping
    Duan, Xianghui
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] OVERALL SURVIVAL IN POST-MENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED BREAST CANCER RECEIVING A CDK 4 AND 6 INHIBITOR plus FULVESTRANT AFTER PROGRESSING ON/AFTER PRIOR ENDOCRINE THERAPY: A FRACTIONAL POLYNOMIAL NETWORK META-ANALYSIS
    Hirst, A.
    Davie, A.
    Carter, Cuyun G.
    Haddad, N.
    Traore, S.
    Brufsky, A.
    Harbeck, N.
    Pivot, X.
    VALUE IN HEALTH, 2020, 23 : S421 - S421
  • [34] Dalpiciclib plus fulvestrant in HR+/HER2-advanced breast cancer (ABC): Updated analysis from the phase III DAWNA-1 trial
    Zhang, P.
    Zhang, Q. Y.
    Hu, X.
    Li, W.
    Tong, Z.
    Sun, T.
    Teng, Y.
    Wu, X.
    Ouyang, Q.
    Yan, X.
    Cheng, J.
    Liu, Q.
    Feng, J.
    Wang, X.
    Xu, G.
    Wu, F.
    Xia, B.
    Xu, B.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S642 - S643
  • [35] Combined chemo-endocrine therapy as a potential new option for HR+/HER2-advanced breast cancer: a prospective study of fulvestrant plus oral vinorelbine
    Wang, Xue
    Yue, Jian
    Kang, Yikun
    Dai, Zhong
    Ju, Jie
    Wang, Jiayu
    Zhang, Pin
    Ma, Fei
    Xu, Binghe
    Yuan, Peng
    CANCER BIOLOGY & MEDICINE, 2023, 20 (04) : 287 - 296
  • [36] Comparative effectiveness of palbociclib plus aromatase inhibitor versus fulvestrant alone as initial endocrine therapy for HR+/HER2-advanced breast cancer in Chinese clinical practice: A real-world study
    Yue, Jian
    Yuan, Peng
    Wang, Xue
    Ju, Jie
    Gao, Song-lin
    Yang, Zixuan
    Kang, Yikun
    Lei, Zixuan
    Shuai, You
    Wei, Tong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Comparative effectiveness of Palbociclib plus Aromatase inhibitor versus fulvestrant alone as initial endocrine therapy for HR+/HER2-advanced breast cancer in Chinese clinical practice: a real-world study
    Yue, Jian
    Wang, Xue
    Ju, Jie
    Yang, Zixiang
    Wei, Tong
    Yuan, Peng
    Gao, Min
    Xu, Ling
    Guan, Yin
    CANCER RESEARCH, 2024, 84 (09)
  • [38] MONARCH 2: Subgroup analysis of patients receiving abemaciclib plus fulvestrant as first- and second-line therapy for HR+, HER2-advanced breast cancer.
    Neven, Patrick
    Johnston, Stephen R. D.
    Toi, Masakazu
    Sohn, Joohyuk
    Inoue, Kenichi
    Pivot, Xavier
    Burdaeva, Olga Nikolaevna
    Okera, Meena
    Masuda, Norikazu
    Koh, Han A.
    Grischke, Eva-Maria
    Conte, Pier Franco
    Lu, Yi
    Haddad, Nadine
    Hurt, Karla
    Kaufman, Peter A.
    Llombart-Cussac, Antonio
    Sledge, George W.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] MONARCH 3: Updated time to chemotherapy and disease progression following abemaciclib plus aromatase inhibitor (AI) in HR+, HER2-advanced breast cancer (ABC)
    Huober, J.
    Martin, M.
    Johnston, S.
    Di Leo, A.
    Sohn, J.
    Andre, V. A. M.
    Martin, H. R.
    Hardebeck, M. C.
    Goetz, M. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 163 - 163
  • [40] NETWORK META-ANALYSIS COMPARING PALBOCICLIB PLUS FULVESTRANT WITH EVEROLIMUS PLUS EXEMESTANE FOR HR+/HER2-ADVANCED BREAST CANCER THAT HAS BECOME RESISTANT TO PREVIOUS ENDOCRINE THERAPY
    LeReun, C.
    Gentilini, A.
    Large, S.
    Chowdhury, M.
    Smith, A.
    Rinciog, C.
    VALUE IN HEALTH, 2019, 22 : S446 - S446
12345